Algo’s topical pain treatment fails Phase 2 study with overperforming placebo
AlgoTherapeutix’s topical non-opioid drug has flunked a mid-stage trial in chemotherapy-induced pain due to a stronger-than-expected placebo arm, but the company is still determined to find a path forward. The Paris-based biotech’s ATX01 did not ...
AlgoTherapeutix’s topical non-opioid drug has flunked a mid-stage trial in chemotherapy-induced pain due to a stronger-than-expected placebo arm, but the company is still determined to find a path forward.
The Paris-based biotech’s ATX01 did not ...
